Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02798679

Enrollment

Registered

2016-06-14

Start date

2016-08-31

Completion date

2022-09-01

Last updated

2022-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiotoxicity

Brief summary

The purpose of this study is to determine whether pre-existing cardiac fibrosis is a predictor of cancer treatment-related cardiotoxicity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

* Stage I-III breast cancer or lymphoma with a \>2 year life expectancy * A treatment plan that includes anthracyclines and/or trastuzumab * Age \>45 years * Able to hold breath for 10 seconds * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion criteria

* Refusal or inability to provide informed consent * Known heart failure or LVEF \<50% * Heart rate over 100 bpm * Renal dysfunction with GFR \<30 mL/min/1.73m2 * Participants with pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices * Symptomatic claustrophobia * Plans to move within 24 months of enrollment

Design outcomes

Primary

Measure	Time frame
Cardiotoxicity assessed clinically or by cardiac MRI	24 months

Countries

United States

Outcome results